SRP-1001
RNA / oligonucleotide
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06131983 NCT06131983 · Facioscapulohumeral Muscular Dystrophy Registry: NCT06131983 | 1/2 | Number of Participants With Treatment-Emergent Adverse Events Over Time Through End of Study (Part 1: Up to Day 90; Part 2: Up to Day 360) 2028-12-31 | In progress: results expected 31 Dec 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Competitive landscape
Other DUX4 drugs
1 other tracked programme targets this mechanism, 1 of them ahead of this one.
This drug's own stage for Facioscapulohumeral Muscular Dystrophy: Phase 1/2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| SRP-1001: this drug | Phase 1/2 | RNA / oligonucleotide | DUX4 | not yet graded | No reviewed efficacy summary in this indication | |
| Delpacibart Braxlosiran | Phase 3 | RNA / oligonucleotide | DUX4 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow SRP-1001 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
December 2028 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent